Selective Targeting of Neuroblastoma Tumour-initiating Cells by Compounds Identified in Stem Cell-based Small Molecule Screens

Overview

Journal EMBO Mol Med

Specialty Molecular Biology

Date 2010 Aug 20

PMID 20721990

Citations 29

Authors

Kristen M Smith

Alessandro Datti

Mayumi Fujitani

Natalie Grinshtein

Libo Zhang

Olena Morozova

Kim M Blakely

Susan A Rotenberg

Loen M Hansford

Freda D Miller

Herman Yeger

Meredith S Irwin

Jason Moffat

Marco A Marra

Sylvain Baruchel

Jeffrey L Wrana

David R Kaplan

Affiliations

Soon will be listed here.

Abstract

Neuroblastoma (NB) is the most deadly extra-cranial solid tumour in children necessitating an urgent need for effective and less toxic treatments. One reason for the lack of efficacious treatments may be the inability of existing drugs to target the tumour-initiating or cancer stem cell population responsible for sustaining tumour growth, metastases and relapse. Here, we describe a strategy to identify compounds that selectively target patient-derived cancer stem cell-like tumour-initiating cells (TICs) while sparing normal paediatric stem cells (skin-derived precursors, SKPs) and characterize two therapeutic candidates. DECA-14 and rapamycin were identified as NB TIC-selective agents. Both compounds induced TIC death at nanomolar concentrations in vitro, significantly reduced NB xenograft tumour weight in vivo, and dramatically decreased self-renewal or tumour-initiation capacity in treated tumours. These results demonstrate that differential drug sensitivities between TICs and normal paediatric stem cells can be exploited to identify novel, patient-specific and potentially less toxic therapies.

Citing Articles

Intrinsic transcriptional heterogeneity in neuroblastoma guides mechanistic and therapeutic insights.

Shendy N, Zimmerman M, Abraham B, Durbin A Cell Rep Med. 2022; 3(5):100632.

PMID: 35584622 PMC: 9133465. DOI: 10.1016/j.xcrm.2022.100632.

Mechanisms involved in selecting and maintaining neuroblastoma cancer stem cell populations, and perspectives for therapeutic targeting.

Farina A, Cappabianca L, Zelli V, Sebastiano M, Mackay A World J Stem Cells. 2021; 13(7):685-736.

PMID: 34367474 PMC: 8316860. DOI: 10.4252/wjsc.v13.i7.685.

Roniciclib down-regulates stemness and inhibits cell growth by inducing nucleolar stress in neuroblastoma.

Ognibene M, Pezzolo A Sci Rep. 2020; 10(1):12902.

PMID: 32737364 PMC: 7395171. DOI: 10.1038/s41598-020-69499-6.

Cancer stem cells in neuroblastoma therapy resistance.

Aravindan N, Jain D, Somasundaram D, Herman T, Aravindan S Cancer Drug Resist. 2019; 2:948-967.

PMID: 31867574 PMC: 6924637. DOI: 10.20517/cdr.2019.72.

Cancer Stem Cells and Neuroblastoma: Characteristics and Therapeutic Targeting Options.

Veschi V, Verona F, Thiele C Front Endocrinol (Lausanne). 2019; 10:782.

PMID: 31803140 PMC: 6877479. DOI: 10.3389/fendo.2019.00782.

References

Zhang , Chung , OLDENBURG . A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen. 2000; 4(2):67-73. DOI: 10.1177/108705719900400206. View

Johnsen J, Segerstrom L, Orrego A, Elfman L, Henriksson M, Kagedal B . Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene. 2007; 27(20):2910-22. DOI: 10.1038/sj.onc.1210938. View

Toma J, Akhavan M, Fernandes K, Sadikot A, Kaplan D, Miller F . Isolation of multipotent adult stem cells from the dermis of mammalian skin. Nat Cell Biol. 2001; 3(9):778-84. DOI: 10.1038/ncb0901-778. View

Konig H, Holtz M, Modi H, Manley P, Holyoake T, Forman S . Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. Leukemia. 2008; 22(4):748-55. DOI: 10.1038/sj.leu.2405086. View

Frank N, Schatton T, Frank M . The therapeutic promise of the cancer stem cell concept. J Clin Invest. 2010; 120(1):41-50. PMC: 2798700. DOI: 10.1172/JCI41004. View

Rotenberg S, Smiley S, Ueffing M, Krauss R, Chen L, Weinstein I . Inhibition of rodent protein kinase C by the anticarcinoma agent dequalinium. Cancer Res. 1990; 50(3):677-85. View

Brideau C, Gunter B, Pikounis B, Liaw A . Improved statistical methods for hit selection in high-throughput screening. J Biomol Screen. 2004; 8(6):634-47. DOI: 10.1177/1087057103258285. View

Laverdiere C, Liu Q, Yasui Y, Nathan P, Gurney J, Stovall M . Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2009; 101(16):1131-40. PMC: 2728747. DOI: 10.1093/jnci/djp230. View

Pampaloni F, Reynaud E, Stelzer E . The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol. 2007; 8(10):839-45. DOI: 10.1038/nrm2236. View

10.

Sancho P, Galeano E, Nieto E, Delgado M, Garcia-Perez A . Dequalinium induces cell death in human leukemia cells by early mitochondrial alterations which enhance ROS production. Leuk Res. 2007; 31(7):969-78. DOI: 10.1016/j.leukres.2006.11.018. View

11.

Maris J, Hogarty M, Bagatell R, Cohn S . Neuroblastoma. Lancet. 2007; 369(9579):2106-20. DOI: 10.1016/S0140-6736(07)60983-0. View

12.

Yilmaz O, Valdez R, Theisen B, Guo W, Ferguson D, Wu H . Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature. 2006; 441(7092):475-82. DOI: 10.1038/nature04703. View

13.

Weiss M, Wong J, Ha C, Bleday R, Salem R, Steele Jr G . Dequalinium, a topical antimicrobial agent, displays anticarcinoma activity based on selective mitochondrial accumulation. Proc Natl Acad Sci U S A. 1987; 84(15):5444-8. PMC: 298874. DOI: 10.1073/pnas.84.15.5444. View

14.

Misawa A, Hosoi H, Tsuchiya K, Sugimoto T . Rapamycin inhibits proliferation of human neuroblastoma cells without suppression of MycN. Int J Cancer. 2003; 104(2):233-7. DOI: 10.1002/ijc.10914. View

15.

Martel R, Klicius J, Galet S . Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol. 1977; 55(1):48-51. DOI: 10.1139/y77-007. View

16.

Zhuo S, Allison W . Inhibition and photoinactivation of the bovine heart mitochondrial F1-ATPase by the cytotoxic agent, dequalinium. Biochem Biophys Res Commun. 1988; 152(3):968-72. DOI: 10.1016/s0006-291x(88)80378-4. View

17.

Sehgal S, Baker H, Vezina C . Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo). 1975; 28(10):727-32. DOI: 10.7164/antibiotics.28.727. View

18.

Marimpietri D, Brignole C, Nico B, Pastorino F, Pezzolo A, Piccardi F . Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis. Clin Cancer Res. 2007; 13(13):3977-88. DOI: 10.1158/1078-0432.CCR-06-2757. View

19.

Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A . Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest. 2008; 118(9):3065-74. PMC: 2518073. DOI: 10.1172/JCI34739. View

20.

Wright R, Wakelin L, Fieldes A, Acheson R, Waring M . Effects of ring substituents and linker chains on the bifunctional intercalation of diacridines into deoxyribonucleic acid. Biochemistry. 1980; 19(25):5825-36. DOI: 10.1021/bi00566a026. View